ACE and prostate cancer: Then, in order to meet the need for clinically relevant models of prostate cancer-associated bone lesions, more recent hormone-independent models have been developed like MDA PCa 118 and Ace-1 that similarly to the PC3c model do not express AR and induce mixed lesions [22,32].